News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Cavan John T
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/20/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/18/2021 |
4
| Cavan John T (CFO) has filed a Form 4 on Hepion Pharmaceuticals, Inc.|
Txns:
| Bought 10,000 shares
@ $2, valued at
$20k
|
|
| 11/30/2020 |
4
| Cavan John T (CFO) has filed a Form 4 on Hepion Pharmaceuticals, Inc.|
Txns:
| Bought 4,500 shares
@ $1.62, valued at
$7.3k
|
|
| 08/21/2020 |
4
| Cavan John T (CFO) has filed a Form 4 on Hepion Pharmaceuticals, Inc.|
Txns:
| Granted 160,000 options
@ $3.72, valued at
$595.2k
|
|
| 04/07/2020 |
4
| Cavan John T (CFO) has filed a Form 4 on Hepion Pharmaceuticals, Inc.|
Txns:
| Granted 215,000 options
@ $1.63, valued at
$350.5k
|
|
| 07/25/2019 |
4
| Cavan John T (CFO) has filed a Form 4 on Hepion Pharmaceuticals, Inc.|
Txns:
| Granted 5,820 options
@ $3.24, valued at
$18.9k
|
|
| 07/03/2018 |
4
| Cavan John T (CFO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc.|
Txns:
| Bought 15 convertible preferred
@ $1000, valued at
$15k
Bought 8,625 warrants
@ $1.55, valued at
$13.4k
|
|
| 01/05/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/21/2017 |
4
| Cavan John T (CFO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc.|
Txns:
| Granted 15,000 options
@ $0.58, valued at
$8.7k
|
|
| 07/07/2017 |
4
| Cavan John T (CFO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc.|
Txns:
| Granted 46,726 shares
@ $0 |
|
| 06/22/2017 |
4
| Cavan John T (CFO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc.|
Txns:
| Bought 20,000 shares
@ $0.65, valued at
$13k
|
|
| 08/29/2016 |
4
| Cavan John T (CFO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc. |
| 04/20/2016 |
3
| Cavan John T (CFO) has filed a Form 3 on ContraVir Pharmaceuticals, Inc. |
| 10/22/2010 |
3
| Cavan John T (VP & Chief Accounting Officer) has filed a Form 3 on Aegerion Pharmaceuticals, Inc. |
|
|